{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Monther A"],"funding":["National Cancer Institute"],"pagination":["e0328031"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12912607"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(2)"],"pubmed_abstract":["Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promise in combination with anti-PD1 immunotherapy in tumors, including recurrent/metastatic HNSCC. We found that CD47 expression is associated with poor prognosis in HNSCC and explored the anti-tumor activity of an anti-CD47 fusion protein in combination with anti-PD1 and lymphatic-sparing radiotherapy in a locally advanced HNSCC model. In the 4MOSC1 syngeneic HPV-negative HNSCC mouse model, ALX301 (a"],"journal":["PloS one"],"pubmed_title":["CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma."],"pmcid":["PMC12912607"],"funding_grant_id":["R01CA281285"],"pubmed_authors":["Al-Msari R","Gutkind S","Philips C","Tang C","Decker K","Sen P","Califano J","Monther A","Saddawi-Konefka R","Fassardi S","Sharabi A","Miyauchi S","Roy S","Mohammadzadeh P","Jones R","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma.","description":"Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promise in combination with anti-PD1 immunotherapy in tumors, including recurrent/metastatic HNSCC. We found that CD47 expression is associated with poor prognosis in HNSCC and explored the anti-tumor activity of an anti-CD47 fusion protein in combination with anti-PD1 and lymphatic-sparing radiotherapy in a locally advanced HNSCC model. In the 4MOSC1 syngeneic HPV-negative HNSCC mouse model, ALX301 (a","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026","modification":"2026-07-16T05:14:32.382Z","creation":"2026-07-09T10:38:16.182Z"},"accession":"S-EPMC12912607","cross_references":{"pubmed":["41701713"],"doi":["10.1371/journal.pone.0328031"]}}